🧫
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-lrrk2-gb
🧫 Experiment Protocol
Validation
Metadata
| experiment_type | validation |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.902180Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['LRRK2'], 'diseases': ["Parkinson's Disease"]} |
| model_system | human |
| summary | # LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD ## Background and Rationale Parkinson's Disease (PD) affects 1-2% of individuals over 65, with genetic mutations in LRRK2 a |
| replication_status | single_study |
| methodology_notes | Phase 1 (Months 1-6): Recruit 500 asymptomatic LRRK2/GBA carriers (aged 50-80, mutation-positive >10 years, MDS-UPDRS-III <6), 300 symptomatic carriers, and 400 matched controls through international |
| primary_outcome | Identification of genetic variants and molecular pathways significantly enriched in asymptomatic LRRK2/GBA carriers compared to affected carriers, validated through iPSC-derived dopaminergic neuron fu |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.902186'} |
Linked Artifacts (2099)